CTLA4 and cancer: Although we still do not know how these pathways play Treg-specific roles, we do know that blocking these co-inhibitory pathways using anti-PD1 and anti-CTLA-4 antibodies promotes anti-cancer activity; such blocking antibodies are used widely for cancer treatment [51].